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Abstract
Background—Diabetic retinopathy (DR) is a microvascular disease that results from retinal 
vascular degeneration and defective repair due to diabetes induced endothelial progenitor 
dysfunction.
Objective—Understanding key molecular factors involved in vascular degeneration and repair is 
paramount for developing effective DR treatment strategies. We propose that diabetes-induced 
activation of acid sphingomyelinase (ASM) plays essential role in retinal endothelial and CD34+ 
circulating angiogenic cell (CAC) dysfunction in diabetes.
Methods—Human retinal endothelial cells (HRECs) isolated from control and diabetic donor 
tissue and human CD34+ CACs from control and diabetic patients were used in this study. ASM 
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mRNA and protein expression was assessed by quantitative PCR and ELISA, respectively. To 
evaluate the effect of diabetes-induced ASM on HRECs and CD34+ CACs function, tube 
formation, CAC incorporation into endothelial tubes, and diurnal release of CD34+ CACs in 
diabetic individuals was determined.
Results—ASM expression level was significantly increased in HRECs isolated from diabetic 
compared to control donor tissue, as well as CD34+CACs and plasma of diabetic patients. A 
significant decrease in tube area was observed in HRECs from diabetic donors as compared to 
control HRECs. The tube formation deficiency was associated with increased expression of ASM 
in diabetic HRECs. Moreover, diabetic CD34+ CACs with high ASM showed defective 
incorporation into endothelial tubes. Diurnal release of CD34+ CACs was disrupted with the 
rhythmicity lost in diabetic patients.
Conclusion—Collectively, these findings support that diabetes-induced ASM upregulation has a 
marked detrimental effect on both retinal endothelial cells and CACs.
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1. Introduction
Diabetic retinopathy (DR) is a microvascular disease that results from diabetes-induced 
retinal damage that is further exacerbated by bone marrow dysfunction. Bone marrow 
dysfunction leads to decreased release of cells into the circulation and changes in 
hematopoiesis resulting in increased circulating pro-inflammatory monocytes and 
diminished repair due to defective progenitor cells. Although DR influence all retinal cells, 
clinical manifestations of DR are mainly due to changes in retinal vessels, where early 
histological alterations include pericyte loss, thickening of basement membrane, capillary 
occlusion and endothelial cell degeneration (1,2). These are followed by break down of 
blood retinal barrier (BRB) and leaky vasculature leading to hemorrhages, hard exudates, 
and retinal edema; structural changes involving the vascular wall leading to 
microaneurysms; and finally neovascularization, vitreous hemorrhage and fibrous tissue 
formation (3). Impaired vision due to macular edema, or vision loss due to 
neovascularization-induced vitreous hemorrhage or tractional retinal detachment usually 
takes place in the later stages of the disease.
Circulating angiogenic cells (CACs), a population of vascular progenitors originated from 
HSC (4), are considered as key regulators for healthy maintenance of retinal vasculature. 
Diabetic metabolic abnormalities lead to defective vascular maintenance due, in part, to 
failed attempts by dysfunctional CACs to repair damaged endothelium.
HSCs isolated from bone marrow or CACs from peripheral blood of control (healthy) 
animals have been shown to repair ischemic damage and aid in reperfusion of ischemic 
tissues (4–6). Several studies have shown an association between DR risk and both reduced 
number (7–10) and function of CACs (11–16).
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Several key hyperglycemia- and dyslipidemia-activated pathways leading to retinal 
endothelial cell and CAC dysfunction have been identified. Prominent among these are 
pathways that promote an increase of pro-inflammatory cytokines, pro-inflammatory lipids 
and pro-angiogenic factors (17–26). We have previously demonstrated activation of the 
central enzyme of sphingolipid metabolism, acid sphingomyelinase (ASM), as a key 
metabolic abnormality in diabetic retinal vasculature and CACs. ASM hydrolyzes 
sphingomyelin (SM) into pro-inflammatory and pro-apoptotic ceramide. Activation of ASM 
plays an important role in signal transduction in response to various stimuli including IL-1β 
(27,28) and TNF-α (29). Endothelial cells represent a major source of ASM (30–33). 
Inhibition of ASM exhibits protective effect in diabetes preventing diabetes-induced retinal 
inflammation and vascular degeneration (15,33,34).
Previously, we have identified key defects in circadian regulation of CACs. We showed that 
bone marrow denervation results in loss of circadian release of vascular reparative cells from 
the bone marrow and generation of increased numbers of proinflammatory cells. Using a rat 
model of T2D, we showed that the decrease in CACs release from diabetic bone marrow is 
caused by bone marrow neuropathy and that these changes precede the development of 
diabetic retinopathy. We observed a marked reduction in clock gene expression in the retina 
and in CACs. Denervation of the bone marrow resulted in progenitors being “trapped” 
within the bone marrow and in loss of the circadian release of these cells into the circulation. 
This reduction in the circadian peak of CAC release into the circulation led to diminished 
reparative capacity and resulted in development of acellular retinal capillaries (7). We also 
showed that Per2 mutant mice recapitulate key aspects of diabetes without the associated 
metabolic abnormalities. In Per2 mutant mice, we observed a threefold decrease in 
proliferation and 50% reduction in nitric oxide levels in CACs. Tyrosine hydroxylase-
positive nerve processes and neurofilament-200 staining were reduced in Per2 mutant mice 
(suggestive of diabetic neuropathy) and increased acellular capillaries were identified (35). 
We also showed that as CD34+CACs acquired differentiation markers (towards the 
endothelial lineage), robust oscillations of clock genes are observed (36).
It is well accepted in diabetic complications field that cells isolated from diabetic tissue keep 
diabetic phenotype for several passages even when cultured in normal glucose. This is due to 
“metabolic memory”, or “legacy effect” for vascular disease in diabetes - the prolonged 
benefits of good glycemic control, as well as the prolonged harm poor control in diabetic 
patients(11,37–39). In this study we used HREC cells isolated from control and diabetic 
donor tissue as a model.
In the current study, we have focused exclusively on human CACs. We asked if the defect in 
circadian release observed in rodents with diabetes occurred in humans. We examined the 
effect of diabetes-induced ASM activity on the function of human CACs and retinal 
endothelial cells comparing the angiogenic ability of control (low ASM) and diabetic (high 
ASM) HRECs to form tube—like structures in vitro and determining the capacity of control 
(with low ASM) and diabetic (with high ASM) CACs to support endothelial tube formation.
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2. Methods
Circadian study of human CD34+ CACs
The study was approved by the University of Florida IRB #411-2010. All study subjects 
provided informed consent. Individuals were brought into the Clinical Research Center at 
the University of Florida for 48 h During the first 24 h, individuals were evaluated and on 
the evening of the first day, a heparin lock was inserted into their forearm. During the second 
24-h period, the individuals had 1 mL of blood removed every 2 h for a total of 24 h and 
analyzed for the number of CD34+ cells by flow cytometry. Clinical characteristics of the 
patients are presented in Table 1.
Postmortem imaging of human retina and cell culture
Primary cultures of HRECs were prepared from postmortem tissue obtained from National 
Disease Research Interchange, Philadelphia, PA and Midwest Eye-Banks, Ann Arbor, MI. 
The tissue was received within 36 h after death. The donor characteristics are provided in 
Table 2. Primary HRECs were isolated as previously described (40). As previously 
demonstrated the cells isolated from control and diabetic donors keep their phenotypes for 
4–6 passages due to metabolic memory phenomenon (11, 37–39). On arriving in the 
laboratory, the eyes were placed on sterile gauze, and they were washed with povidone- 
iodine solution (Purdue Pharma L.P. Stamford, CT). After 10 minutes, the globe was 
punctured approximately 2 mm from the limbus, a circumferential incision was made and 
the anterior chamber was removed. A vitreous spatula was used to loosen the vitreous 
adherent to the anterior retina. When all the vitreous was removed, the retina was gently 
removed from the layer of retinal pigment epithelium and cut at the optic nerve. Before 
proceeding into the isolation of HRECs, retinas were rinsed, flatmounted and retinal 
imaging was taken using a Nikon SMZ-800 Stereo Microscope with Prior Proscan 3 
Motorized XY System with Z Drive and MetaMorph Modules to perform image stitching, to 
properly determine the stage of retinopathy of the donors used for isolation of HRECs. 
Retinas included in this study have at least three signs of non-proliferative diabetic 
retinopathy (NPDR) such as microaneurysms, intraretinal haemorrhages and intraretinal 
microvascular abnormalities (IRMA). Retina was then placed on a 53-μm Nylon mesh filter 
(Sefar America, Buffalo, NY.), washed with a solution containing Glucose (5.5 mM), L-
Glutamine (2 mM) and 1x MEM Non-Essential Amino Acids Solution (GIBCO, Life 
Technologies, Carlsbad, CA). The retinas were then placed into a 25-ml flask containing 100 
U/ml of collagenase, Type 1 (Worthington Biochemical Co., Lakewood, NJ) in the above-
mentioned solution containing 22% Bovine serum albumin (Sigma) and 0.01% Soybean 
Trypsin Inhibitor (Sigma). Retinas were then mechanically agitated using a shaker and 
allowed to digest at 37°C for approximately 60 minutes or until no tissue fragments could be 
seen. After digestion, cells were centrifuged at 1000 rpm for 5 minutes. The supernatant was 
removed and pellet was suspended in fresh media; 1:1 mix of low glucose Dulbecco’s 
modified Eagle’s medium (DMEM 1g/L)/F-12 nutrient mix (GIBCO, Life Technologies, 
Carlsbad, CA) supplemented with 10 % fetal calf serum (Hyclone, Logan, UT), 1% 
endothelial cell growth supplement (Millipore, MA), 1% insulin-transferrin- sodium selenite 
media supplement (Sigma) and 1% penicillin-streptomycin antimycotic (GIBCO, 
Invitrogen-Life Technologies, Carlsbad, CA). Glucose concentration in the final media was 
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adjusted to 5.5 mM. The cells were maintained at 37°C in 95% air and 5% CO2 in a 
humidified cell culture incubator. Passages 3 to 5 were used in the experiments.
Human CD34+ CACs isolation
Human peripheral blood samples (150 ml) were collected into Sodium Citrate-containing 
CPTTM glass vacuum tubes (BD, Franklin Lakes, NJ). Written informed consent was 
obtained from each patient, and all procedures were approved by the Institutional Review 
Board at the University of Florida (IRB # 408-2010). Peripheral blood mononuclear cells 
(MNCs) were isolated from the blood by density gradient centrifugation using Lympholyte 
(Cedarlane Laboratories Ltd., Ontario, Canada). The CD34+ cell fraction was then isolated 
from the MNCs using the EasySepTM CD34+ positive selection system according to the 
manufacturer’s instructions (Stem Cell Technologies, Vancouver, BC, Canada). Clinical 
characteristics of the patients are presented in Table 2.
Tube formation assay
Tube formation assay was performed using BD BioCoat Angiogenesis System-Endothelial 
Cells Tube Formation Matrigel Matrix 96-well plate (BD Biosciences Discovery Labware, 
Bedford, MA) according to the manufacturer’s instructions. Briefly, isolated CD34+ CACs 
and HRECs were labeled with Qtracker 655 and Qtracker 525 (Invitrogen); respectively. 
Control or diabetic HRECs were mixed in a 4:1 ratio with either control or diabetic CD34+ 
cells, seeded into Matrigel Matrix 96-well plate) and incubated for 16 to 18 h at 37°C (5% 
CO2). After incubation, wells were assessed for the presence of tube-like structures and 
images were taken in 10× magnifications using a Nikon TE2000 fluorescence microscope 
equipped with Photometrics CoolSNAP HQ2 camera. At least three different fields were 
randomly selected and captured to collect images for each well. Tube area and percentage of 
CD34+ incorporated into tubules were calculated using MetaMorph software system 
(Molecular Devices, Downingtown, PA). Statistics were performed on 3 independent wells 
per condition with minimum three images taken from each well.
Quantitative real-time PCR
Total RNA was extracted from HRECs, human CD34+ cells using QuickGene RNA 
(Fujifilm, Minato-Ku, Tokyo, Japan) or Qiagen RNeasy (Qiagen Inc., Valencia, CA, USA) 
according to the manufacturer’s instructions. NanoDrop 2000 (Thermo Scientific, IL, USA) 
was used to determine total RNA concentration. Total RNA was reverse transcribed into 
cDNA using superscript III first-strand synthesis system (Invitrogen, Carlsbad, CA). Human 
gene-specific primers for ASM were used. Expression levels were normalized to human 
cyclophilin. Sequence of specific primers used is given below:
Human ASM: caacctcgcgctgaagaa and tccaccatgtcatcctcaaa
Human Cyclophilin: aaggtcccaaagacagcaga and cttgccaccagtgccattat
ELISA assay
Blood samples were collected, centrifuged and plasma was stored at −80 °C. Samples were 
assayed for human ASM concentration using ELISA kit (Cloud–Clone Corp., Houston, TX, 
USA) according to the manufacturer’s protocol.
Kady et al. Page 5
J Clin Lipidol. Author manuscript; available in PMC 2018 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Statistical analyses—Data are presented as mean ± S.E.M. Results were analyzed for 
statistical significance by the Student’s t-test (GraphPad Prism 7, GraphPad Software, San 
Diego, CA). Significance was established at P < 0.05.
3. Results
ASM expression level is increased in HREC, CD34+ CACs and blood plasma of diabetic 
donors
To determine whether human diabetic tissues exhibited the same increase in ASM as we 
observed in animal models (15,33), we measured ASM expression level in human RECs, 
CD34+ CACs and plasma samples in both diabetic and control donors. ASM expression 
level was significantly increased in all three tissue types in diabetic compared to control 
donors (Fig. 1A, B and C).
Diabetes induces decrease in HREC tube formation
As shown above and previously demonstrated, HRECs isolated from diabetic donors have 
high ASM activity and expression level. To evaluate the effect of diabetes-induced increase 
in ASM on HRECs function, we performed tube formation assay to measure the ability of 
retinal endothelial cells to form blood-vessel-like tubular structure. Tube formation by 
HRECs isolated from healthy control retinas was compared to cells isolated from retinas 
with signs of NPDR as determined by post-mortem retinal imaging (Fig. 2A). A significant 
decrease in tube area was observed in HRECs from retinas with signs of NPDR as compared 
to control HRECs (Fig. 2B).
Diabetes induced increase in ASM is associated with CD34+ CACs dysfunction
To determine the role of ASM expression in diabetes-induced defect in CD34+ CACs 
function, we seeded CD34+ CACs isolated from both control (low ASM) and diabetic (high 
ASM) subjects with HRECs and examined whether the level of ASM expression in CACs 
affects their ability to incorporate into the endothelial tubes formed by the HRECs. 
Interestingly, CD34+ CACs seeded alone did not form tube-like structures, but they did 
incorporate into tubes formed by HRECs when co-cultured with retinal endothelial cells 
(Fig. 3C). Increased incorporation into tubes formed by diabetic HRECs was observed for 
the control CD34+ CACs (low ASM) compared to diabetic CACs (high ASM) (Fig. 3B). As 
expected, control HRECs exhibited robust tube formation. Incorporation of CACs into 
control HREC tubes was not affected by the levels of ASM in CAC (Fig. 3A). These data 
demonstrate that high ASM expression levels in CD34+ CACs correlate with impaired 
incorporation ability, while CACs expressing lower levels of ASM display enhanced in vitro 
incorporation.
Diabetes induced increase in ASM is associated with loss of circadian release of CD34+ 
CACs
We have previously demonstrated that normal diurnal pattern of CACs release from the bone 
marrow is critical for efficient repair of retinal vasculature in rodents (7). Increase in ASM 
activity in CACs in diabetic animal models was associated with decreased membrane 
fluidity and impaired migration leading to increased CAC retention and loss of circadian 
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release from the bone marrow (34). We next determined the effect of diabetes on circadian 
release of CD34+ CACs in diabetic patients. Peripheral blood of type 2 diabetic individuals 
was collected every 2 h for 24 h and analyzed for the number of CD34+ CACs by flow 
cytometry and compared with control subjects. The dash line is the model fitted curve for 
individual subjects and bold curve is the fitted curve for population (Fig. 4 A and B). In 
agreement with previous studies, healthy individuals had a peak of circulating CD34+ cells 
in the middle of the night, representing the rest phase for humans (Fig. 4A), however this 
peak of CD34+ release was lost in T2D subjects (Fig. 4B).
4. Discussion
Diabetic retinopathy is a sight threatening complication of diabetes with limited treatment 
strategies. Understanding the key molecular factors involved in the disease is important for 
developing therapeutic targets to prevent progression into ocular neovascularization and 
blindness. ASM is shown to be a key element in inflammatory signaling through ceramide-
mediated signal transduction (41,42). Diabetes-induced increase in ASM activity has been 
shown to modulate inflammatory response in mature retinal endothelial cells (43), however, 
there is no direct experimental evidence showing ASM effect on endothelial function. Here 
we demonstrated that HRECs isolated from type 2 diabetic subjects with signs of NPDR had 
altered retinal endothelial cell function with impaired capacity to form tube-like structures 
when compared with control HRECs. The deficiency in tube formation was associated with 
increased expression of ASM in diabetic HRECs. This is consistent with previous studies 
showing ASM–mediated endothelial cell apoptosis in various tissues including retina, lungs 
and gastrointestinal tract (30,31,33,44), and ASM antiangiogenic effect in tumor treatment 
(45). Endothelium is the major source of ASM production in the body with endothelial cells 
synthesizing 20 times as much ASM as any other cell type (32); thus, it is not surprising that 
ASM plays a major role in endothelial cells function. In agreement with previous studies 
(32), endothelial cells had very high ASM expression level, which was further increased in 
diabetes. Moreover, increased ASM level in plasma further reflects the increased production 
and secretion of ASM by activated endothelial cells.
Retinal vascular repair and revascularization is aided by CACs (4,13,16,46–49). We 
examined the effect of diabetes-induced increase in ASM on the ability of CD34+ CACs to 
incorporate and thus help in repair of defective vascular-like tube structures formed by 
diabetic HRECs. We demonstrated that diabetic CD34+ CACs, with high ASM, showed 
minimal incorporation into the defective tubes formed by diabetic HRECs. Non-diabetic 
CD34+ CACs with low ASM showed robust incorporation. These results are in line with 
other studies showing that diabetic CACs are defective in proliferation, migration, adhesion, 
differentiation, and participation in vascular regeneration process (13,14,16,46,50,51). 
Interestingly, no significant difference was observed between non-diabetic and diabetic 
CD34+ CACs incorporation into control HRECs. This is consistent with our previous studies 
demonstrating lack of incorporation of control CACs into healthy vasculature that does not 
require repair in non-diabetic (13). We have previously demonstrated that high level of ASM 
inversely correlates with migration and reparative capacity of CACs, with the inhibition of 
diabetes-induced ASM resulting in improved migration and retinal vascular regeneration in 
diabetic mouse model (15,34).
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In this study, we compared effect of ASM on functional capacity of healthy and diabetic 
CACs in human on control and diabetic HRECs. We revealed that the defective 
incorporation of diabetic CD34+ CACs was associated with high ASM. As previously 
shown, high ASM activity leads to accumulation of membrane ceramides. Accumulation of 
ceramide results in decreased membrane fluidity, cell rigidity and defective migration which 
can explain defective incorporation of diabetic CACs (15,34,52) and likely supports their 
defective release from the bone marrow into the systemic circulation.
Although several lines of evidence demonstrate that ASM expression is an important factor 
for progenitor cell release from the marrow, migration, proliferation and homing to the 
injured vasculature; other factors beyond ASM activation are also known to be involved in 
diabetes-induced CAC dysfunction. These include bone marrow neuropathy and low level of 
neurotransmitters production; increase in TGF beta leading to decreased NO bioavailability 
and diminished expression of CXCR4 (7,53). These factors affect chemoattraction to SDF1 
and lead to increase in stem cell quiescence in the bone marrow niche. In health ASM works 
in concert with other factors to maintain optimal bone marrow stem cell production and 
release, however activation of ASM along with other factors disrupts this balance in diabetes 
(7,34,54,55).
The physiological release of bone marrow progenitor cells including CD34+ CACs into the 
circulation is not constant, but follows circadian oscillations. These oscillations are regulated 
by sympathetic signaling to bone marrow stromal cells, which results in CXCL12 (SDF-1) 
down regulation and progenitor egress from the bone marrow; all of these processes occur in 
circadian pattern under control of clock genes (56). Diabetic bone marrow neuropathy with 
disruption of circadian rhythm may contribute to endothelial progenitor cell dysfunction. 
Wang et al. have demonstrated that mutation in circadian gene Per2 leads to reduced 
endothelial cell progenitor mobilization and revascularization (57). We investigated whether 
circadian release of CD34+ CACs is altered in diabetic subjects. Peripheral blood was 
collected every 2 h for 24 h from both control and diabetic subjects. In agreement with 
previous studies (58–60), normal rhythmic oscillations were observed in control subjects 
with a clear peak of circulating CD34+ CACs cells in the middle of the night (resting phase), 
optimal time of regeneration in humans. Similar to our observations in diabetic rat model 
(7). This study revealed that circadian fluctuation of CD34+ CACs was disrupted with 
rhythmicity lost in diabetic individuals. Importantly, we have previously demonstrated that, 
similar to endothelial cells, the increase in ASM activity in CACs in diabetic animal models 
was associated with increased ceramide levels, decreased membrane fluidity and impaired 
migration. This impairment in migration, combined with diminished sympathetic signaling 
to BM may lead to increased CAC retention in the bone marrow and loss of circadian release 
of the progenitor cells as demonstrated in this study.
5. Conclusion
This study underscores the deleterious effect of high ASM levels on the vascular repair 
potential of both mature retinal endothelial cells and circulating angiogenic cells in diabetes. 
Correcting this defect could treat vasodegeneration, enhancing vessel repair and thus 
preventing progression into PDR stage.
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Highlights
• Increase of acid sphingomyelinase (ASM) in diabetes damages retinal 
vasculature.
• CD34+CACs from diabetic patients with high ASM have dysfunctional 
vascular repair.
• Diabetic individuals showed disrupted diurnal release pattern of CD34+CACs.
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FIG. 1. Diabetes induced increase in ASM expression
Total RNA was isolated and the transcript level of ASM was analyzed by qRT-PCR in (A) 
HRECs, (B) CD34+ cells and (C) plasma from diabetic donors (n=4–7) compared with 
control donors (n=3−4). Data are means ± SEM. *P < 0.05, significantly different as 
determined by Student’s t-test. Abbreviations: ASM, acid sphingomyelinase; HRECs, 
human retinal endothelial cells.
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FIG. 2. Diabetes impairs tube formation capacity of HRECs
(A) Postmortem imaging of human retina. Control retina with well-organized blood vessels 
(left), Diabetic retina with signs of NPDR; intraretinal hemorrhages and microaneurysms 
(right). (B) An in vitro tube formation assay was performed in control (n=4) and diabetic 
(n=7) HRECs using Matrigel Matrix 96-well plate. Representative images of tube-like 
structures are shown. The cells were stained with Qtracker 525 (green), images were taken 
in 10× magnification and total tube areas were calculated using MetaMorph software 
system. Quantification of tube area is shown on far right. Data are means ± SEM. *P < 0.05, 
significantly different as determined by Student’s t -test. Scale bar = 50 μm.
Kady et al. Page 15
J Clin Lipidol. Author manuscript; available in PMC 2018 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIG. 3. Reduced incorporation of diabetic CD34+ CACs into diabetic HRECs tubes
Tube formation by HRECs (Qtracker 525, green) isolated from control (A) or diabetic (B) 
donors either without CACs (left panel), or co-incubated with control (middle panel) or 
diabetic (right panel) CACs (Qtracker 655, red) is shown. Quantification of % of CD34+ 
CACs incorporation into HRECs tubes is shown on far right. Data are means ± SEM (n= 
4−7). *** P < 0.0001, significantly different from control as determined by Student’s t -test; 
not significant at P > 0.05. Scale bar = 50 μm. (C) CD34+ CACs alone were not able to form 
tube-like structures (left panel), but incorporated into HREC tubes, forming tube-like 
structures, when co-cultured with HRECs (right three panels). Abbreviations: CACs, 
circulating angiogenic cells.
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FIG. 4. Loss of circadian release of diabetic CD34+ CACs
Peripheral blood was collected every 2 h for a total of 24 h from (A) control (n=4) and (B) 
diabetic (n=8) subjects and was analyzed for the number of CD34+ CACs by flow 
cytomtery. (A) In control subjects, there is a clear peak of circulating CD34+ CACs that 
occurred in the middle of the night. (B) Rhythmic CD34+ CACs release pattern was blunted 
in Type 2 diabetic patients. The dash line is the model fitted curve for individual patients and 
bold curve is the fitted curve for population.
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